Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mequinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573464 | 0.94 | KDM4E (0.65) | KDM4ENPC1L3MBTL1RAB9AKMT2A | |
| SCHEMBL4810431 | 0.76 | CYP1A2 (0.52) | KDM4EL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL13219481 | 0.76 | CYP1A2 (0.52) | KDM4EL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL1556194 | 0.76 | CYP1A2 (0.52) | KDM4ENPC1L3MBTL1RAB9AKMT2A | |
| SCHEMBL29828916 | 0.76 | CYP1A2 (0.52) | KDM4EL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL11808148 | 0.75 | COMT (0.61) | KDM4ENPC1L3MBTL1RAB9AMAPT | |
| SCHEMBL5773989 | 0.74 | CYP1A2 (0.51) | KDM4ENPC1L3MBTL1RAB9AKMT2A | |
| SCHEMBL454942 | 0.74 | CYP1A2 (0.55) | KDM4EL3MBTL1RAB9AKMT2AMEN1 | |
| SCHEMBL3563100 | 0.74 | KMT2A (0.55) | KDM4EL3MBTL1KMT2AMEN1MAPT | |
| Anthracene SCHEMBL8925919 | 0.74 | ESR2 (0.64) | KDM4ENPC1RAB9ACYP1A2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | claimed |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | VISIGEN BIOTECHNOLOGIES, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9845500-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160244822-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation | 2016-08-25 | — | — | US | disclosed |
| US-9243284-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140127781-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2014-05-08 | — | — | US | disclosed |
| US-8648179-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130102050-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation (US) | 2013-04-25 | — | — | US | disclosed |
| US-8314216-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110184163-A1 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis | Life Technologies Corporation (US) | 2011-07-28 | — | — | US | disclosed |
| US-20100255464-A1 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation | 2010-10-07 | — | — | US | disclosed |
| US-20100216122-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: METHODS FOR DIRECT DETECTION OF TAGGED MONOMERS | Life Technologies Corporation (US) | 2010-08-26 | — | — | US | disclosed |
| US-20070172860-A1 | Enzymatic nucleic acid synthesis: compositions and methods | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172869-A1 | Enzymatic nucleic acid synthesis: methods for inhibiting pyrophosphorolysis during sequencing synthesis | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172859-A1 | Enzymatic nucleic acid synthesis: methods for direct detection of tagged monomers | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | Life Technologies Corporation | 2007-07-26 | — | — | US | disclosed |
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1354064-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | Visigen Biotechnologies, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
| WO-2002044425-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184163-A1 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis | RNGTT, PPA1, PNP | KDM4E 2979/4885NPC1 3834/4885L3MBTL1 2804/4885 |
| US-20070172819-A1 | Enzymatic nucleic acid synthesis: compositions including pyrophosphorolysis inhibitors | RNGTT, PPA1, PNP | KDM4E 2547/4885NPC1 3764/4885L3MBTL1 2942/4885 |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | RNGTT, PPA1, PNP | KDM4E 2933/4885NPC1 3739/4885L3MBTL1 2798/4885 |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | RNGTT, PNP, MTAP | KDM4E 2908/4885NPC1 4174/4885L3MBTL1 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.